Navigation Links
Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
Date:2/22/2011

STEVENSVILLE, Md., Feb. 22, 2011 /PRNewswire-USNewswire/ -- Vapotherm, the global leader in High Flow Therapy (HFT™) products, has received 510(k) clearance from the Food and Drug Administration (FDA) for the Flowrest® homecare device.  The device also recently received CE marking.

The Flowrest® delivers warmed, humidified high-flow breathing gases to patients via nasal cannula. Utilizing patent pending humidification and breathing circuit technology, the device is designed to maximize ease of use and patient comfort, both of which are critical in homecare and other low acuity settings.  

"We are excited to expand our leadership position in HFT™ with the launch of this device intended specifically for homecare use," said Robert Storey, CEO of Vapotherm.  "Our hospital customers have been asking us for a solution to enable earlier discharge of high flow therapy patients, and patients and families have consistently asked us to deliver a cost effective solution for comfortable, effective respiratory support in the home.  We are pleased to answer this need with Flowrest®, which will address the broad population of patients who benefit from heated and humidified high flow breathing gases."

High Flow Therapy via nasal cannula is utilized in hospitals throughout the world to provide respiratory support for spontaneously breathing adult, pediatric and neonatal patients with a variety of acute or chronic conditions.  Clinical practice and research has demonstrated that its use can help clinicians avoid more invasive respiratory therapies.  Vapotherm's gas conditioning technology allows for high flows to be delivered via a simple nasal cannula, allowing patients to avoid the discomfort and confinement of mask therapy.

Vapotherm, Inc. is a privately held manufacturer of respiratory care devices for hospitals and homecare use based in Stevensville, Maryland. The Company is dedicated to the development of innovative, non-invasive technologies for respiratory therapy, especially for the treatment of chronic lung and acute breathing disorders. For more information, visit www.vtherm.com.Contact:

Kevin ThibodeauEVP of Sales & Marketing410-604-3977
'/>"/>

SOURCE Vapotherm, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):